The World Health Organization (WHO) validated on Tuesday the CoronaVac COVID-19 vaccine developed by Chinese pharmaceutical company Sinovac Biotech for emergency use.

WHO recommends the vaccine for use in people 18 years and older, in a two-dose schedule with a spacing of two to four weeks, according to a statement.

The efficacy results showed that the Sinovac vaccine prevented symptomatic disease in 51 percent of those vaccinated, and prevented severe COVID-19 and hospitalization in 100 percent of the studied population, according to the WHO's Strategic Advisory Group of Experts on Immunization (SAGE).

What do you want to know about China's Sinovac COVID-19 vaccine? We've invited Yin Weidong, chairman and CEO of Sinovac, to answer your questions.

Produced by Xinhua Global Service